New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 11, 2012
12:40 EDTGEVASynageva BioPharma announces 6 month data from extension study of SBC-102
Synageva BioPharma announced six month results from an ongoing extension study of sebelipase alfa in adults with late onset Lysosomal Acid Lipase, LAL, Deficiency at the American Association for the Study of Liver Diseases, AASLD, annual meeting being held in Boston, MA, November 9-13.
News For GEVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 16, 2014
10:01 EDTGEVAOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:53 EDTGEVASynageva initiated with a Buy at SunTrust
Target $117.
October 8, 2014
10:06 EDTGEVASynageva announces sebelipase alfa Phase 3 study data presentation
Synageva BioPharma announced that data from its Phase 3, global clinical study evaluating sebelipase alfa in children and adults with LAL Deficiency has been selected for oral presentation during the late-breaking session at The Liver Meeting, the 65th Annual Meeting of the American Association for the Study of Liver Diseases, being held November 7-11. The data will be presented during the late-breaking oral session on November 10.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use